Prevention of progression and remission/regression strategies for chronic renal diseases: Can we do better now than five years ago?
- 1 September 2005
- journal article
- review article
- Published by Elsevier in Kidney International
- Vol. 68 (98) , S21-S24
- https://doi.org/10.1111/j.1523-1755.2005.09804.x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathiesKidney International, 2003
- Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2003
- Effect of angiotensin II antagonism on the regression of kidney disease in the ratKidney International, 2002
- Combination ACEI and ARB therapy: additional benefit in renoprotection?Current Opinion in Nephrology and Hypertension, 2002
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaThe Lancet, 1999
- Pathophysiology of Progressive NephropathiesNew England Journal of Medicine, 1998
- Reversal of Lesions of Diabetic Nephropathy after Pancreas TransplantationNew England Journal of Medicine, 1998